October 15, 2010 -- Roche announced that Tarceva, one of its blockbuster monoclonal cancer drugs, proved to be very effective against a specific form of lung cancer in a China trial. The drug almost tripled the progression-free survival in patients with non-small cell lung cancer (NSCLC) that has the EGFR mutation. In China, about 30% of NSCLC cancers exhibit EGFR, while it is present in just 10% of western NSCLC patients. More details...
